4151
Kyowa Kirin Co.,Ltd.
協和キリン
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Dec 2021
352,246
Dec 2022
398,371
Dec 2023
442,233
Dec 2024
495,558
Dec 2025
496,826
Operating profit(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Operating profit margin(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Profit before tax(million JPY)
Dec 2021
60,050
Dec 2022
67,572
Dec 2023
97,246
Dec 2024
83,453
Dec 2025
87,221
Profit(million JPY)
Dec 2021
52,347
Dec 2022
53,573
Dec 2023
81,188
Dec 2024
59,870
Dec 2025
67,040
Total assets(million JPY)
Dec 2021
921,872
Dec 2022
939,881
Dec 2023
1,025,942
Dec 2024
1,067,363
Dec 2025
1,107,860
Cash and cash equivalents(million JPY)
Dec 2021
335,084
Dec 2022
339,194
Dec 2023
403,083
Dec 2024
244,681
Dec 2025
218,769
Cash flows from operating activities(million JPY)
Dec 2021
86,548
Dec 2022
48,672
Dec 2023
115,551
Dec 2024
67,884
Dec 2025
96,619
Cash flows from investing activities(million JPY)
Dec 2021
-11,363
Dec 2022
-17,185
Dec 2023
-20,382
Dec 2024
-142,387
Dec 2025
-89,189
Cash flows from financing activities(million JPY)
Dec 2021
-28,446
Dec 2022
-29,032
Dec 2023
-32,535
Dec 2024
-84,697
Dec 2025
-36,853
Return on equity(%)
Dec 2021
7.3
Dec 2022
7.1
Dec 2023
10.2
Dec 2024
7.1
Dec 2025
7.7
Equity ratio(%)
Dec 2021
80
Dec 2022
81.2
Dec 2023
81.5
Dec 2024
79.7
Dec 2025
80.6
Earnings per share(JPY per share)
Dec 2021
97.43
Dec 2022
99.68
Dec 2023
151.03
Dec 2024
113.06
Dec 2025
128.07
Net assets per share(JPY per share)
Dec 2021
1,371.9
Dec 2022
1,419.27
Dec 2023
1,555.81
Dec 2024
1,625.68
Dec 2025
1,706.5
Dividend per share(JPY per share)
Dec 2021
46
Dec 2022
51
Dec 2023
56
Dec 2024
58
Dec 2025
62
Payout ratio(%)
Dec 2021
47.21
Dec 2022
51.16
Dec 2023
37.08
Dec 2024
51.3
Dec 2025
48.41
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.